DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
08 Maio 2023 - 9:50AM
Business Wire
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company currently focused on developing
recombinant KLK1 (DM199) for the treatment of acute ischemic
stroke, announced today that its first quarter 2023 financial
results will be released after the markets close on Monday, May
15th. DiaMedica will host a live conference call on Tuesday, May
16th at 7:00 AM Central Time to provide a business update and
discuss financial results.
Conference Call details:
Date:
Tuesday, May 16, 2023
Time:
7:00 AM CT / 8:00 AM ET
Web access:
https://app.webinar.net/r4298p1YBXV
Dial In:
(877) 550-1858
Conference ID:
2125#
Interested parties may access the conference call by dialing in
or listening to the simultaneous webcast. Listeners should log on
to the website or dial in 15 minutes prior to the call. The webcast
will remain available for play back on our website, under investor
relations - events and presentations, following the earnings call
and for 12 months thereafter. A telephonic replay of the conference
call will be available until May 23, 2023, by dialing (800)
645-7964 (US Toll Free) and entering the replay passcode:
2125#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases. DiaMedica’s lead candidate
DM199 is the first pharmaceutically active recombinant (synthetic)
form of the KLK1 protein, an established therapeutic modality in
Asia for the treatment of acute ischemic stroke and chronic kidney
disease. For more information visit the Company’s website at
www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230508005416/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi Corporate Communications Phone: 617-899-5941
ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
